Paris-based Eligo Bioscience raises €27.7 million Series B to to create a novel class of transformative genetic medicines

Published on December 5, 2023

Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful €27.7 million Series B funding round, led by Sanofi Ventures. This infusion of capital, supported by new investor Bpifrance (through its InnoBio 2 fund), and existing backers Khosla Ventures and Seventure…

This content is for members only. Visit the site and log in/register to read.

The post Paris-based Eligo Bioscience raises €27.7 million Series B to to create a novel class of transformative genetic medicines appeared first on EU-Startups.

Continue reading on website
Other news

Empowering Academic Founders: The Spinoff Prize 2024 is now accepting applications (Sponsored)

December 5, 2023
The Spinoff Prize is a prestigious global award from Nature and Merck that offers a €30,000 prize plus international visibility to early-stage university spinouts. This award provides a unique and free opportunity for academic entrepreneurs to increase their company’s profile and attract potential investors. It is designed to enhance the visibility of these entrepreneurs and… This content is for m

Madrid-based Strong by Form secures €4.8 million to bring a sustainable alternative to concrete

December 5, 2023
Strong by Form, a leading bio-composite technology company, announced the successful completion of its seed funding round, raising €4.8 million. The round was oversubscribed by more than 25% and was led by CMPC Ventures, the corporate venture capital arm of CMPC, one of the world’s largest pulp and paper producers. Alongside CMPC Ventures, the seed… This content is for members only. Visit the site